Nuformix PLC on Monday celebrated multiple patent wins, after grants in both Europe and the US signalled further protections for its fibrosis and oncology technology.

Nuformix is a London-based developer of treatments for fibrosis and oncology via drug repurposing. Its shares were trading 12% higher at 0.22 pence each in London on Monday morning.

The grants were for the multiple patents held by Nuformix for NXP002, its lead asset and a potential novel inhaled treatment for idiopathic pulmonary fibrosis.

The European Patent Office formally issued a grant of patent number 3837238 on June 12, covering NXP002 drug forms being progressed as a potential novel IPF treatment.

Meanwhile, the US Patent & Trademark Office issued a grant of patent application 17/365,490, covering use of the Nuformix’s proprietary drug forms in the treatment of various diseases including fibrotic lung diseases.

The US PTO also granted patent number 12012386, representing the first granted patent in the second NXP004 cocrystal series.

Nuformix’s NXP004 programme is focused on the development of novel, proprietary, cocrystal forms of olaparib, a drug currently marketed by AstraZeneca PLC, under the Lynparza brand name.

‘I’m delighted we’ve received these multiple grants of key patents underpinning both our NXP002 and NXP004 programmes. The European patent grant represents the last major territory to confirm protection of the novel drug forms enabling NXP002’s development as a potential novel IPF treatment,’ said Executive Director Dan Gooding.

Copyright 2024 Alliance News Ltd. All Rights Reserved.